Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: SY 801

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese Academy of Medical Sciences
  • Developer Beijing Union Pharmaceutical; Chinese Academy of Medical Sciences
  • Class Antineoplastics; Antivirals; Biphenyl compounds; Hepatoprotectants; Small molecules
  • Mechanism of Action Cytochrome P-450 enzyme system stimulants; Free radical scavengers; Gap junction modulators; Glutathione transferase stimulants; HSP70 heat shock protein stimulants; Protein kinase C inhibitors; Proto-oncogene protein c-myc stimulants; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fatty liver; Viral hepatitis
  • No development reported Liver cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in China (PO, Tablet)
  • 13 Jul 2015 Bicyclol is covered by patent protection (Beijing Union website, July 2015)
  • 18 Nov 1996 Preclinical development for Viral hepatitis in China (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top